Table 2.
Post Hoc Analyses
| Patients developing LRTC, n/N (%) | Presatovir | Placebo | Treatment Difference (95% CI), % | Nominal P Valuea |
|---|---|---|---|---|
| Lymphopenia, <200 cells/µL | 2/15 (13.3) | 9/14 (64.3) | −51.0 (−77.8 to −13.1) | .008 |
| No ribavirin use | 4/64 (6.3) | 12/68 (17.6) | −11.4 (−28.1 to 5.9) | .061 |
| Symptom duration ≤ median, 4 daysb | 5/48 (10.4) | 13/49 (26.5) | −16.1 (−35.4 to 3.4) | .066 |
| Hospitalized on Day 1 | 7/39 (17.9) | 11/24 (45.8) | −27.9 (−50.9 to −2.4) | .023 |
| ≤365 days after HCT | 5/50 (10.0) | 12/47 (25.5) | −15.5 (−34.8 to 4.7) | .061 |
Data are for LRTC development through Day 28 by presence of lymphopenia, duration of symptoms, hospitalization status, and time after HCT at Day 1. Data for other efficacy endpoints and subgroups are provided in Supplementary Tables 4–9.
Abbreviations: CI, confidence interval; HCT, hematopoietic cell transplant; LRTC, lower respiratory tract complications.
a P values were calculated using the Fisher exact test.
bThe median duration of respiratory symptoms on Day 1 in the efficacy population was 4 days.